Abstract
4095 Background: Management of LA pancreatic cancer patients (pts) remains controversial. Whatever the treatment administered (CT or RCT), median survival is around 10 months. In order to select pts who will potentially benefit from CRT, the therapeutic strategy used by the GERCOR group consisted in initial CT for at least 3 months. Decision of CRT or further CT in non progressive pts was based on investigator’s discretion. Methods: We retrospectively analyzed the outcome of 181 LA pancreatic cancer pts (76F/105M, mean age 61 years, range 37–85) enrolled in prospective phases II (Folfugem 1 and 2, Gemox) and III (Gem-Gemox) GERCOR studies in order to compare survival of pts who received CRT and pts who continued on CT alone. Results: Median progression-free survival (PFS) and overall survival (OS) were for the whole population (181 pts) 6.3 and 11.4 months, respectively. Among the 181 pts, after 3 months of CT, 53 (29.3%) had a disease progression and were then not eligible for CRT. Among the 128 remainin...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
